• Newron Pharmaceuticals’ 433,070 newly issued shares are set to begin trading on SIX Swiss Exchange under the existing ISIN.
• Secondary listings are expected on Düsseldorf’s Primärmarkt, with trading on Frankfurt’s Quotation Board (Xetra).
• The shares were issued in a EUR 5.5 million second tranche of an investor-led financing tied to the ENIGMA-TRS Phase 3 program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.